Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Cautious Thorchain update compounds ZCash woes as vulnerability headache grows

Cautious Thorchain update compounds ZCash woes as vulnerability headache grows

CryptopolitanCryptopolitan2026/06/05 18:39
By:Cryptopolitan

THORChain has remained offline for three weeks since it experienced a $10.7 million vault exploit.

THORChain initially planned to integrate ZEC support into its platform, but even that is now delayed after a critical flaw was discovered in Zcash’s Orchard shielded pool. That decision could not have come at a worse time for ZEC, which has taken a beating since the AI–discovered vulnerability was revealed.

What happened to THORChain and when will it restart?

THORChain has been offline for three weeks following a major security breach that resulted in the loss of $10.7 million from one of its vaults.

The problem at THORChain started with a flaw in a security system called the GG20 threshold signature scheme. An attacker was able to join the network as a node operator and exploit this weakness to drain funds from a single vault. The other four vaults were not affected.

THORChain’s developers released a fix (version 3.19) several days ago, but the network is yet to resume normal operations.

The team even added a new safety step called “key verify” to ensure every remaining vault is secure before operations resume. The restarting process will include node operators moving to the new software version, migrating funds, and finally reopening trading. Barraford estimated that this process will take several days to complete once it begins.

The recovery plan, called ADR028, aims to cover the $10.7 million loss without creating new RUNE tokens or diluting existing holders. Instead, the protocol’s own money will be used, and any remaining loss will be shared with synthetic asset holders. The protocol is also offering the hacker a bounty to return the funds.

What was the Zcash bug, and why did it cause such a big price drop?

Zcash was supposed to be THORChain’s next chain integration, ahead of Monero, but that timeline slipped after security researcher Taylor Hornby, working under contract with Shielded Labs, discovered a soundness bug in Zcash’s Orchard shielded pool.

The bug has been present in the Orchard protocol “rulebook” since it launched in May 2022. Hornby used Anthropic’s Opus 4.8 model to create a working example of the exploit in a test environment and confirmed it could produce fake tokens in a local test environment.

An emergency soft fork quickly temporarily disabled Orchard transactions on June 2, and a hard fork (NU6.2) reactivated the pool with a corrected circuit on June 3. The five-day turnaround from discovery to resolution was only the second security-driven protocol upgrade in Zcash’s ten-year history.

When the bug was disclosed, ZEC dropped roughly 40% within 24 hours. CoinMarketCap data showed the token trading near $333, down from a 52-week high above $700.

Arthur Hayes, the chief investment officer at Maelstrom and co-founder of BitMEX, said on X that he liquidated his entire ZEC position. Hayes previously set a public price target of 10% of Bitcoin’s value for ZEC, but the 30% drop forced him to rethink.

He left open the possibility of buying back the tokens if his concerns about supply integrity proved unfounded.

Blockchain intelligence firm Arkham flagged at least one large holder who watched more than half the value of a $174 million ZEC position evaporate without selling.

Shielded Labs, the organization that fixed the bug, explained that it is cryptographically impossible to determine whether or not the bug was ever used due to the four-year window before it was found, but the firm also stated that it is unlikely the bug could have evaded years of expert review if it was active.

Just discovering the vulnerability required AI-assisted auditing techniques, and the remediation window was narrow once the flaw became known.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23